These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 30737243)

  • 1. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
    Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
    Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
    Miao G; Sun X
    Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
    Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
    Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response.
    Lin TY; Tsai TH; Chen CT; Yang TW; Chang FL; Lo YN; Chung TS; Cheng MH; Chen WC; Tsai KC; Lee YC
    Exp Anim; 2021 Aug; 70(3):333-343. PubMed ID: 33716253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction, expression and functional analysis of anti-B7-H4- scFv-CH3 recombinant antibody.
    Ji H; Guo J; Yang Y; Xu C; Mao W
    J Biosci; 2018 Sep; 43(4):661-671. PubMed ID: 30207312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
    Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
    J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
    Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
    J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
    Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
    Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.
    Dangaj D; Scholler N
    Methods Mol Biol; 2015; 1319():37-49. PubMed ID: 26060068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
    Kim GE; Kim NI; Park MH; Lee JS
    Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.